From StructContinue beyond “Veeva’s Supplier Is Also Building a Rival”Back to the brief ↗Feed / ALNY

Alnylam Pharmaceuticals, Inc.

ALNY

Healthcare · 216.05 -5.5% today

You’ve read what changed. Here’s whether the market is confirming it.

IsolatedMarket checked 6 Aug, 15:55 GMT-4

Jodie situation report

Alnylam Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 22 directly disclosed connections are confirming.

Company-5.5% todayVolume comparison unavailable
Market group0 of 37 activeTransportation · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • A routine FDA inspection at a CMO resulted in a pending '61' inspection classification, prompting an amendment to the vutrisiran submission and delaying the PDUFA action date and NDA approval.

Invalidation: The isolated read changes if ALNY's group or a disclosed connection begins moving with it.

Watch this read